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Immunological Unresponsiveness Characterized by
Increased Expression of CD5 on Peripheral T Cells
Induced by Dendritic Cells In Vivo
distinct mechanisms including deletion, anergy, and ex-
trinsic suppression by regulatory T cells (Apostolou et
al., 2002; Asano et al., 1996; Critchfield et al., 1994;
Friedman and Weiner, 1994; Jenkins and Schwartz,
1987; Jones et al., 1990; McCormack et al., 1993;
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3 Center for Neurologic Diseases and Shevach, 1998; Van Parijs et al., 1996). Deletion
physically removes autoreactive cells from the periph-Brigham and Women’s Hospital and
Harvard Medical School eral T cell pool (Critchfield et al., 1994; Rocha and von
Boehmer, 1991). In contrast, T cell anergy is a cell auton-Boston, Massachusetts 02115
omous phenomenon that appears to result from incom-
plete T cell stimulation and negative signaling by
CTLA-4, PD-1, PD-2, and possibly other receptorsSummary
(Gross et al., 1990; Latchman et al., 2001; Nishimura et
al., 1999; Perez et al., 1997; Tivol et al., 1995). AnergicIn the steady state, interaction between T cells and
T cells differ from naive T cells in that they are unrespon-antigen-presenting dendritic cells (DCs) leads to T cell
sive to TCR crosslinking (Schwartz, 2003). Finally, T reg-tolerance. To examine the role of DC regulated periph-
ulatory cells actively suppress immunity (Asano et al.,eral tolerance in a model autoimmune disease, we
1996). Although unrelated, all these mechanisms removedelivered an encephalitogenic oligodendrocyte glyco-
self-reactive T cells from the immune repertoire by inac-protein (MOG) peptide to DCs in vivo. We found that
tivating T cell responses.targeting MOG peptide to DCs resulted in a novel form
Here we report on a new mechanism for peripheralof peripheral T cell tolerance that was sufficiently pro-
T cell tolerance whereby self-reactive T cells are sparedfound to prevent autoimmune experimental acute en-
from deletion and remain highly responsive to activationcephalomyelitis (EAE). The tolerized T cells were se-
by TCR cross-linking but fail to respond to antigenverely impaired in specific secondary responses to
in vivo. This form of T cell inactivation is induced byantigen in vivo but they were not intrinsically anergic
steady state DCs in the periphery and depends on in-since they remained highly responsive to T cell recep-
creased expression of CD5 on tolerant T cells.tor (TCR) stimulation in vitro. The mechanism that me-
diates this dynamic antigen-specific T cell unrespon-
siveness differs from previously described forms of Results
tolerance in that it requires that DCs induce CD5 ex-
pression on activated T cells. Prevention of EAE
To examine whether antigen targeted to DCs in the
steady state can protect mice from autoimmune diseaseIntroduction
we chose a well-characterized myelin oligodendrocyte
glycoprotein (MOG) peptide that elicits EAE (Grewal etRandom antigen receptor assembly produces a diverse
T cell receptor repertoire that includes an unknown num- al., 1996; Kuchroo et al., 2002; Legge et al., 2002; Mendel
et al., 1995; Menges et al., 2002; Miller et al., 1995;ber of self-reactive and potentially self-destructive
T cells. Tolerance is achieved in part by inactivating or Smilek et al., 1992). DC targeting was achieved using
an antibody to DEC-205, an endocytic receptor highlydeleting such T cells in the thymus (Anderson et al.,
2002; Kappler et al., 1987; Kisielow et al., 1988; Mat- expressed by DCs that carries antigens into intracellular
antigen processing compartments (Figure 1A) (Jiang etzinger and Guerder, 1989). However, not all self-antigens
can be found in the thymus, and additional mechanisms al., 1995; Mahnke et al., 2000). To confirm that the engi-
neered hybrid antibody, denoted DEC/MOG, was tar-for regulating self-reactive T cells must operate in the
periphery. Peripheral T cell tolerance has been demon- geted to, processed, and presented by DCs, mice were
injected intraperitoneally with 15 g of the hybrid anti-strated to be an active process that required interaction
between T cells and bone marrow derived dendritic cells body and DCs and other lymphoid cells were assayed for
antigen presentation to MOG-specific transgenic CD4(Adler et al., 1998; Belz et al., 2002; Bonifaz et al., 2002;
De Smedt et al., 1996; Finkelman et al., 1996; Hawiger T cells (Bettelli et al., 2003) (Figure 1B). DCs harvested
1 day after injection with DEC/MOG induced stronget al., 2001; Jung et al., 2002; Kurts et al., 1997, 2001;
Morgan et al., 1999; Probst et al., 2003; Sallusto and T cell proliferative responses whereas DCs isolated from
PBS-injected mice or mice injected with isotype controlLanzavecchia, 1999; Scheinecker et al., 2002; Schulz
and Reis e Sousa, 2002). III/10/MOG antibody did not (Figure 1B). In contrast to
DCs, B cells and CD11cCD19 mononuclear cells puri-Peripheral T cell tolerance is maintained by several
fied from the same mice showed little antigen-present-
ing activity even when additionally stimulated with anti-*Correspondence: nussen@mail.rockefeller.edu
CD40 in vitro (Figure 1B). Finally, DCs isolated from mice4 Present address: Yale School of Medicine, Section of Immunobiol-
ogy, New Haven, Connecticut 06520. injected with DEC antibodies expressed levels of CD86
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Figure 1. DC Targeting by DEC/MOG Prevents EAE in C57Bl/6 Mice
(A) Diagrammatic representation of hybrid antibodies.
(B)DEC/MOG delivers MOG peptide to DCs in vivo. Anti-MOG transgenic T cell proliferation in vitro, as measured by 3H-thymidine incorporation,
in response to CD11c, CD19, and CD11c CD19 cells isolated from lymph nodes 24 hr after intraperitoneal injection of 15 g of DEC/
MOG or III/10/MOG or PBS. Anti-CD40 antibody (CD40 L) was added as indicated.
(C) Disease prevention. Three groups each of 10 C57Bl/6 mice were pre-injected i.p. with either PBS or 15 g of DEC/MOG or III/10/MOG
7 days before challenge with 100 g MOG peptide in CFA subcutaneously, and PTX i.p. Disease symptoms scored on days 14 and 21
postimmunization gave similar results.
(D) CD4 cells in the spinal cord at day 21 postimmunization. Histograms show staining with anti-CD4 among cells in the “lymphoid” gate of
spinal cord cell suspensions. The results shown in (B), (C), and (D) represent one of three independent experiments.
and MHC II similar to those found on DCs from PBS then induced EAE by injection of 100 g MOG peptide
in Complete Freund’s Adjuvant (CFA) and Pertussis toxincontrols and thus showed no signs of increased matura-
tion (see Supplemental Figure S1 at http://www.immunity. (PTX). In this model, pre-treatment with large doses of
free peptide in the absence of adjuvants leads to protec-com/cgi/content/full/20/6/695/DC1). We conclude that
DEC/MOG selectively targets DCs in vivo and that the tion from subsequent challenge with peptide in CFA plus
PTX (Kuchroo et al., 2002). We found that mice treatedtargeted DCs process the hybrid antibodies to load
MOG peptide onto MHC II. with the isotype control antibody III/10/MOG or PBS
developed symptoms of EAE (Figure 1C). In contrast,To determine whether DEC/MOG targeting induces
T cell tolerance we treated C57Bl/6 mice with 15 g of DEC/MOG treated mice remained completely disease
free (Figure 1C). To obtain an objective measure of theDEC/MOG or control III/10/MOG antibody or PBS and
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effect of DEC/MOG on T cell effector function, we ex- nized with MOG peptide in CFA  PTX, and therefore
anti-MOG transgenic T cells can be used to follow anti-amined the spinal cords of treated and control mice by
flow cytometry. Whereas increased numbers of CD4 MOG T cell responses in vivo.
Next, we studied whether pre-treatment with DEC/cells could be identified in spinal cords of mice that
showed symptoms of EAE, no such cells were found in MOG prevents transgenic T cells from accumulating in
the CNS. Transfer recipients were injected with DEC/spinal cords of mice that had been pre-treated with
DEC/MOG (Figure 1D). Thus, treatment with DEC/ MOG or III/10/MOG control 7 days before induction of
EAE by injection of MOG peptide in CFA  PTX. Pre-MOG prevents accumulation of effector T cells in the
central nervous system (CNS). We conclude that vacci- treatment of transfer recipients with the control III/10/
MOG had no effect on disease induction or accumula-nation with DEC/MOG induces profound T cell toler-
ance to MOG and prevents induction of EAE. tion of transgenic or non-transgenic T cells in the CNS
(Figure 2C). In contrast, DEC/MOG pre-treated recipi-
ents remained disease free with no accumulation ofMOG Transgenic T Cells
transgenic or non-transgenic T cells in their spinal cordsIn an attempt to define the mechanism that mediates
despite normal numbers of transgenic T cells in lymphtolerance to MOG, we used anti-MOG TCR transgenic
nodes (Figure 2D). We conclude that like endogenousmice on the B6 background where these cells constitute
T cells, anti-MOG transgenic T cells do not accumulateapproximately 80% of CD4 T cells (Bettelli et al., 2003).
in the spinal cords of DEC/MOG pre-treated mice.CD45.2 transgenic T cells were labeled with 5-(6)-car-
boxyfluorescein diacetate succinimidyl diester (CFSE)
to measure cell division, and transferred to CD45.1 Steady State DCs Induce CD5
To determine whether the unresponsive T cells wereC57Bl/6 recipient mice, which were then challenged with
various forms of MOG. Transferred transgenic T cells phenotypically distinct, we examined their cell surface
features by flow cytometry. We found that T cells toler-divided rapidly in response to 100 g of MOG peptide
in CFA or as little as 15 g of DEC/MOG and showed ized by steady state DCs resembled immunized T cells
in most respects. Both groups upregulated expressiona minimal response to 15 g of the control antibody III/
10/MOG (Figure 2A). We conclude that anti-MOG trans- of CD44 and CD69 3 days after challenge and expression
of CD44 remained elevated after 7 days (Figure 3). Wegenic T cells respond to antigen targeted to DCs by
DEC/MOG in vivo. found no change in expression of markers associated
with regulatory T cells such as CD25, ICOS, or CD28,Targeting a model antigen, hen egg lysozyme (HEL)
with DEC hybrid antibodies to DCs in the steady state and both groups downregulated CD62L expression (Fig-
ure 3). The only surface antigen that was found to differresulted in deletion of anti-HEL-specific T cells (Hawiger
et al., 2001). To determine whether anti-MOG-specific between transgenic T cells stimulated by DEC/MOG
and T cells stimulated by MOG peptide in CFA plus PTXT cells were deleted after encountering their cognate
antigen on steady state DCs we performed additional in vivo was CD5. CD5 was upregulated at both 3 and
7 days after challenge with DEC/MOG but was notadoptive transfer experiments. We found that antigen
challenge with DEC/MOG or MOG peptide in CFA  elevated after immunization with MOG peptide in
CFA PTX or PBS (Figure 3). Similar changes in CD5PTX did not lead to T cell deletion (Figure 2B). 3 or 7
days after treatment with DEC/MOG or MOG peptide expression were seen in anti-MOG TCR transgenic mice
treated with DEC/MOG in the absence of adoptivein CFA  PTX we found 4% anti-MOG transgenic
T cells in the lymph nodes of both sets of mice and transfer (Supplemental Figure S3). We conclude that
treatment with DEC/MOG leads to enhanced CD5 ex-1.5% in PBS controls. Furthermore, flow cytometry pro-
vided no evidence of increased apoptosis in the DEC/ pression on antigen-specific peripheral T cells (CD5hi
T cells).MOG-injected mice (Supplemental Figure S2). Thus,
anti-MOG, like anti-HEL transgenic T cells, proliferate
in response to antigen presented by DC s in the steady Role of CD5 in Negative Regulation
state but in contrast to anti-HEL transgenic T cells, such In vivo, CD5 is an inducible negative regulator of thymo-
activation does not lead to subsequent deletion of anti- cytes undergoing selection (Azzam et al., 1998, 2001;
MOG- specific T cells. Lozano et al., 2000; Tarakhovsky et al., 1995; Wong et
al., 2001). In vitro, CD5 is a modulator of T cell responses
with both stimulatory and inhibitory activities (Spertini etMOG Transgenic T Cell Tolerance
To confirm that anti-MOG TCR transgenic T cells partici- al., 1991; Verwilghen et al., 1992). To determine whether
CD5 regulates anti-MOG transgenic T cell activation, wepate in EAE responses like their non-transgenic counter-
parts, we measured their accumulation in the CNS of measured T cell responses to TCR crosslinking in vitro.
CD5hi T cells from DEC/MOG treated mice were readilytransfer recipients after inducing EAE with MOG peptide
in CFAPTX. Transfer recipients developed EAE symp- activated by TCR and coreceptor crosslinking as mea-
sured by increased sensitivity to anti-CD3 and anti-CD28toms similar to those observed in control C57Bl/6 mice
and showed accumulation of CD4 T cells in their spinal crosslinking compared to naive controls (Figure 4, simi-
lar results were obtained with MOG peptide presentedcords (Figure 2C). Among these CD4 T cells 5%–8%
were transgenic T cells (CD45.2TCR11) (Figure 2C) by DCs in vitro, Supplemental Figure S4). In agreement
with the work of others, we observed enhanced prolifer-whereas lymph nodes from the same mice showed only
0.3%–0.6% transgenic T cells (Figure 2D). We conclude ation of naive transgenic T cells after TCR cross-linking
with CD5 engagement (Figure 4). In contrast, transgenicthat like endogenous T cells, anti-MOG transgenic
T cells are enriched in the spinal cords of mice immu- T cells that had been activated by antigen presented by
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Figure 2. Anti-MOG Transgenic T Cell Responses
(A) Anti-MOG transgenic T cells divide in response to antigen presented by DCs in vivo. Histograms show CFSE dye dilution of gated
populations of CD4 CD45.2 TCR11 anti-MOG transgenic T cells 5 days after challenge with 15 g of DEC/MOG or III/10/MOG or 100 g
MOG peptide in CFA  PTX or PBS.
(B) Antigen-specific T cells are not deleted. Anti-MOG transgenic T cells transferred as in (A) and challenged i.p. 24 hr later with 15 g of
DEC/MOG or 100 g MOG peptide in CFA  PTX or PBS. Plots show lymph node cells analyzed by flow cytometry after 3 or 7 days, anti-
CD45.2 (Y axis) and TCR11 (X axis) gated on CD4 cells. The numbers indicate the percentage of CD45.2/TCR11 double positive cells
among CD4 T cells.
(C) Anti-MOG transgenic T cells migrate to spinal cord. CD45.2 anti-MOG transgenic T cells were transferred into CD45.1 C57Bl/6 recipients
that were injected i.p. with 15 g of DEC/MOG or III/10/MOG or PBS 24 hr after transfer and after another 7 days challenged with 100 g
MOG peptide in CFA  PTX. The mice were monitored for disease symptoms daily and scored on days 14 and 21 postimmunization. Mice
Peripheral Tolerance by CD5 Upregulation
699
Figure 3. Surface Antigen Expression after
Activation by DEC/MOG
Anti-MOG transgenic T cells were transferred
into CD45.1 C57Bl/6 mice and 24 hr later,
the recipients were injected intraperitoneally
with 15 g of DEC/MOG or 100 g MOG
peptide in CFA  PTX or PBS. Cells from
lymph nodes were analyzed by flow cytome-
try 3 or 7 days after antigen challenge. Histo-
grams show expression of indicated CD anti-
gens on CD4CD45.2TCR11 cells. Thin
lines in histograms are PBS injected controls.
The results represent one of three indepen-
dent experiments.
steady state DCs showed less proliferation after con- by immunization with MOG peptide in CFA  PTX re-
sponded vigorously to re-challenge with antigen in vivocomitant cross-linking of TCR and CD5 (Figure 4). We
conclude that T cell activation by DEC/MOG does not (Figure 5A). In contrast, T cells that had been pre-acti-
vated by DEC/MOG were unresponsive when chal-render them intrinsically anergic to TCR ligation in vitro.
lenged with MOG peptide in CFA  PTX (Figure 5A). To
determine whether cell death was a major componentTolerance Is CD5 Dependent
of the unresponsiveness, we measured markers of apo-To determine whether T cells activated by DEC/MOG
ptosis on antigen-specific cells activated byDEC/MOGwere unresponsive to further stimulation in vivo, we la-
and challenged with MOG peptide in CFA PTX in vivo.beled T cells from mice pre-treated with DEC/MOG
We found no evidence for cell death or deletion in suchwith CFSE, and measured cell division in response to
cells (Supplemental Figures S5 and S6, A, B, and C).MOG in CFA  PTX or PBS after adoptive transfer. We
found that naive T cells and T cells previously activated We conclude that anti-MOG transgenic T cells originally
were sacrificed on day 21 after disease induction and cells from spinal cord, lymph node, and spleen were analyzed by flow cytometry. Upper
panel, histograms show intensity of staining with anti-CD4 among cells in the “lymphoid” gate of spinal cord cell suspensions. Lower panel,
plots show staining with anti-CD45.2 (Y axis) and TCR11 (X axis) gated on CD4 cells from the lymphoid gate of spinal cord suspensions.
(D) Plots show staining with anti-CD45.2 (Y axis) and TCR11 (X axis) on CD4 lymphocytes from peripheral lymph nodes. The results shown
in (A), (B), (C), and (D) represent one of three independent experiments.
Immunity
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Figure 4. Tolerized T Cells Remain Responsive to TCR Stimulation but Become Susceptible to Inhibition by CD5 Engagement
Cross-linking of CD5 inhibits in vitro response of T cells preactivated in vivo by DEC/MOG. Anti-MOG TCR transgenic mice were injected
with 15 g of DEC/MOG or PBS and after 7 days isolated T cells were cultured with simultaneous cross-linking of their CD3, CD28, and
CD5 by corresponding primary antibodies  secondary polyclonal antibodies. T cell proliferation was measured by 3H-thymidine incorporation.
activated in response to antigen presented by DCs in the Belz et al., 2002; Bonifaz et al., 2002; De Smedt et al.,
1996; Hawiger et al., 2001; Jung et al., 2002; Kurts etsteady state become unresponsive to further challenge
al., 1997, 2001; Liu et al., 2002; Morgan et al., 1999;with antigen in vivo.
Probst et al., 2003; Sallusto and Lanzavecchia, 1999;To determine whether CD5 is involved in producing
Scheinecker et al., 2002; Schulz and Reis e Sousa, 2002).T cell unresponsiveness in vivo, we injected mice with
For example, bone marrow- derived cells induce dele-anti-CD5 antibody. Anti-MOG transgenic mice were
tional T cell tolerance in mice expressing ovalbumin intreated with DEC/MOG in vivo and T cells were trans-
the pancreas (Adler et al., 1998; Kurts et al., 1997). Directferred to naive recipients, where they were challenged
targeting of antigen to steady state DCs showed thatwith MOG in CFA  PTX in the presence or absence of
DCs induce peripheral deletion of antigen-specific CD4anti-CD5 (Figure 5B). We found that T cell unrespon-
and CD8 T cells (Bonifaz et al., 2002; Hawiger et al.,siveness was reversed by anti-CD5 (Figure 5B). We con-
2001). Antigen targeting with antibodies to DEC-205 wasclude that antigen presentation by steady state DCs
a highly efficient method for inducing tolerance requiringinduces CD5 expression by antigen-specific T cells in
very small doses of the targeting antibody, possibly be-the periphery and that increased levels of CD5 could
cause the targeting antibody is widely distributed reach-contribute to CD5hi T cell unresponsiveness in vivo
ing DCs in all secondary lymphoid tissues (Hawiger etand in vitro.
al., 2001). Finally, tolerance is induced by antigen-bear-Injection of antibodies such as anti-CD5 can impact
ing DCs manipulated ex vivo and re-injected into miceon T cell function by a variety of different mechanisms
or humans (Dhodapkar and Steinman, 2002; Legge etincluding Fc receptor and complement-mediated ef-
al., 2002; Menges et al., 2002). Targeting MOG with anti-fects. To confirm the results of the anti-CD5 antibody
DEC-205 extends earlier studies to mice with an intactexperiment and to determine whether CD5 is required
T cell repertoire in a model autoimmune disease andfor DC-induced T cell unresponsiveness in the periph-
the results are consistent with the idea that in the steadyery, we bred CD5/ anti-MOG TCR transgenic C57Bl/6
state antigen presentation by DCs maintains peripheralmice. CD5/ anti-MOG transgenic T cells responded
T cell tolerance.with normal proliferation and upregulation of CD44 sur-
T cell deletion, T regulatory cells, and T cell anergy
face expression after initial challenge with DEC/MOG
are well established mechanisms for maintaining T cell
in vivo (Figure 5C). They differed from CD5/ T cells in
tolerance; each can be induced by DCs in the periphery
that they remained responsive to re-challenge with MOG (Adler et al., 1998; Belz et al., 2002; Bonifaz et al., 2002;
in CFA PTX (Figure 5D). Thus, CD5 is required for DC- De Smedt et al., 1996; Hawiger et al., 2001; Jung et al.,
induced CD5hi T cell unresponsiveness in vivo. 2002; Kurts et al., 1997, 2001; Morgan et al., 1999; Probst
et al., 2003; Sallusto and Lanzavecchia, 1999; Scheinecker
Discussion et al., 2002; Schulz and Reis e Sousa, 2002). How DCs
mediate such profoundly different outcomes of T cell
We have shown a new mechanism by which DCs inacti- activation is not understood but may be a function of
vate T cell responses to self-antigens in the periphery. the affinity of the TCR for antigen as well as of the state
CD5hi T cells are not intrinsically anergic in the classic of differentiation or activation of the DC (Caux et al.,
sense, since they remain highly responsive to TCR 1994; Pierre et al., 1997).
cross-linking or stimulation by cognate antigen in vitro. Our experiments show a new mechanism whereby
Instead, unresponsiveness is associated with dynamic DCs determine the outcome of their interaction with
inhibition of secondary T cell responses in vivo through T cells. Steady state peripheral DCs presenting MOG
CD5, which is induced when naive T cells are activated in vivo induce tolerance by tuning T cell responses
by steady state DCs. through CD5 induction.
DCs and Tolerance CD5
Bone marrow-derived cells mediate peripheral tolerance CD5 (Ly-1, T1/Leu-1) is a 67 kDa type I cell surface
protein with a large cytoplasmic domain containing mul-in a number of experimental systems (Adler et al., 1998;
Peripheral Tolerance by CD5 Upregulation
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Figure 5. CD5 Is Required for Unresponsiveness In Vivo
(A) Transgenic T cells pre-activated with DEC/MOG show impaired responses to antigen challenge in vivo. TCR transgenic mice were injected
with 15 g of DEC/MOG or 100 g MOG peptide in CFA  PTX or PBS, and 7 days later CD4 cells were isolated, labeled with CFSE, and
transferred into CD45.1 C57Bl/6 mice. 24 hr after transfer recipients were challenged with 100 g MOG peptide in CFA  PTX or PBS and
LNs were analyzed 3 days later. The histograms show CFSE intensity of CD4CD45.2TCR11 cells.
(B) Anti-CD5 restores responsiveness in vivo. Pre-treatment with DEC/MOG and cell transfer was as in (A) except that recipients were
challenged with 100 g MOG peptide in CFA PTX with () or without (-) 100 g anti-CD5 antibody and 3 days later LNs were analyzed by
flow cytometry. Histograms show CFSE intensity on gated populations of CD45.2TCR11cells.
(C) CD5/ anti-MOG transgenic T cells respond to DEC/MOG in vivo. CD5/CD45.2 anti-MOG transgenic T cells were labeled with CFSE
and transferred into CD45.1 C57Bl/6 mice and 24 hr later the recipients were challenged with 15 g of DEC/MOG or PBS. Lymph nodes
were analyzed after 6 days by flow cytometry. Histograms show indicated marker expression on CD45.2TCR11 cells.
(D) CD5 is required for un-responsiveness. CD5/ anti-MOG transgenic mice and CD5 / littermates were injected with 15 g of DEC/MOG
or PBS and after 7 days CD4 T cells were isolated, labeled with CFSE, and transferred into CD45.1 C57Bl/6 mice. Recipients were challenged
with 100 g MOG peptide in CFA  PTX or PBS and LNs analyzed 3 days later by flow cytometry. Histograms show CFSE intensity on
CD45.2TCR11 cells. The results shown in (A) and (B) represent one of three and (C) and (D) two similar experiments.
tiple potential phosphorylation sites that recruit positive MHC were found to upregulate CD5 expression, thereby
limiting their responses to self and ensuring self-toler-and negative regulators of T cell signaling (Huang et al.,
1987; Lozano et al., 2000; Perez-Villar et al., 1999). Dur- ance in the periphery (Azzam et al., 1998, 2001). In the
absence of CD5 upregulation T cells that would normallying thymocyte development CD5 is a negative regulator
of TCR signaling that directly influences the threshold be positively selected were deleted (Azzam et al., 1998,
2001; Tarakhovsky et al., 1995). Thus, CD5 levels setfor T cell activation (Azzam et al., 1998, 2001; Tarakhov-
sky et al., 1995). Thymocytes with high affinity for self- thresholds for TCR signaling in the thymus thereby ex-
Immunity
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panding the repertoire of TCRs that can be positively se- Our experiments point to a new mechanism for tuning
lected. mediated by antigen presentation by steady state DCs.
One of the limitations of the current study is the fact Steady state DC-T cell interactions result in T cell activa-
that we were unable to induce EAE in CD5/ mice or tion and CD5 expression. CD5hi T cells are resistant to
animals treated with anti-CD5 antibody. This might be re-challenge by antigen because they are dynamically
expected from the altered T cell selection and TCR acti- altered through CD5 expression but they are not deleted
vation thresholds in the absence of CD5 (Azzam et al., as was the case with tolerance to HEL or OVA antigens
2001; Sun et al., 1992; Tarakhovsky et al., 1995). Conse- (Bonifaz et al., 2002; Hawiger et al., 2001). Furthermore,
quently, we can only speculate about the function of CD5hi T cells do not inhibit activation of naive cells to
CD5 in autoimmunity and this issue awaits a further the same antigen in vivo and cannot regulate naive cells
clarification to distinguish between diverse costimula- in co-transfer experiments (Supplemental Figure S9).
tory and inhibitory properties of this molecule. We find This additional tolerance mechanism resembles anergy
that CD5 expression is induced on peripheral T cells by in that T cells remain viable (Pape et al., 1998; Perez
steady state DCs, and that this leads to proliferative et al., 1997). However, CD5-mediated tuning of T cell
unresponsiveness to antigenic re-challenge in vivo. How responses differs from the type of anergy induced by
CD5 modulates TCR signaling in the thymus is not other inhibitory receptors such as CTLA-4 in that it does
known. The extracellular domain of CD5 is dispensable not interfere with TCR signaling directly (Gross et al.,
for its effects on thymocytes (Bhandoola et al., 2002). 1990; Krummel and Allison, 1995; Latchman et al., 2001;
In addition, thymocytes expressing high levels of CD5 Perez et al., 1997; Tivol et al., 1995; Walunas et al., 1994).
are unresponsive to anti-CD3 stimulation in vitro (Azzam In contrast to anergy, CD5hi T cells tolerized by steady
et al., 1998, 2001). Consequently CD5 is believed to act state DCs remain highly responsive to TCR crosslinking:
in a ligand-independent manner during thymic develop- this might be explained by a requirement for CD5 en-
ment. In contrast to its effects on thymocytes, we find gagement or alternatively CD5 could be brought into
that increased CD5 expression alone is not sufficient to immunological synapse by a yet to be described mecha-
inactivate peripheral CD5hi T cells because such T cells nism. In conclusion, T cell tolerance mediated by upreg-
remain highly responsive to TCR cross-linking in vitro. ulation of CD5 in the periphery is a mechanism that
Simultaneous cross-linking of CD5 and TCR is required might spare autoreactive T cell clones that cross-react
to inhibit antigen-specific responses by peripheral CD5hi with higher affinity to unrelated foreign antigens, thereby
T cells. Furthermore, absence of CD5 prevents induction maintaining tolerance while preserving diversity in the
of unresponsiveness by steady state DCs, and adminis- T cell repertoire.
tration of anti-CD5 antibodies in vivo restores T cell
responsiveness (Figure 5). Thus, peripheral T cells differ Experimental Procedures
from thymocytes in that the effects of CD5 appear to
Micebe dependent on CD5 engagement. We speculate that
6- to 8-week-old females were used in all experiments and werethe effects of CD5 on peripheral T cell responses are
maintained under specific pathogen free conditions. C57Bl/6 andmediated through the immunological synapse since
B6.SJL mice were purchased from Jackson Laboratory. Anti-MOG
CD5 is required for the late events of synapse-mediated TCR transgenic mice were maintained by crossing with C57Bl/6
signal transduction (Brossard et al., 2003). mice or C57Bl/6 CD5/ mice (Joliat et al., 2002). Mice were injected
Thymic CD5 levels were shown to decrease in the intraperitoneally (i.p.) with hybrid antibodies. All experiments with
mice were performed in accordance with NIH guidelines and ap-periphery in the absence of contact with thymus re-
proved by the Rockefeller University animal care and use committee.stricted antigens and the lower CD5 levels were associ-
ated with enhanced sensitivity to TCR cross-linking
Immunization with MOG Peptide and EAE Induction(Smith et al., 2001; Stamou et al., 2003). Thymic levels of
To induce EAE, 6- to 8-week-old C57Bl/6 or B6.SJL females wereCD5 can be maintained by chronic exposure to specific-
injected with 100g MOG peptide in CFA (Difco) (200l total volume,
peptide-MHC and the higher levels of CD5 on these 100 l in each flank). This was followed by intraperitoneal injection
chronically stimulated T cells have been associated with with 200 ng pertussis toxin (List Biological Laboratory) in PBS. An-
tolerance. Whether CD5 plays an active role in this type other dose of 200 ng pertussis toxin was injected 48 hr later. CFA
was enriched with Mycobacterium tuberculosis (10 ml CFA  40of tolerance has not been determined (Barthlott et al.,
mg M. Tuberculosis from Difco)2003; Kassiotis et al., 2003). Nevertheless, T cells that
maintain high levels of CD5 by chronic antigen exposure
Clinical Scoreare anergic to TCR stimulation in vitro (Stamou et al.,
Clinical score was determined on days 14 and 21 after immunization.2003). In contrast, CD5 induction by steady state DCs
0, no clinical signs; 1, flaccid tail; 2, hind limb weakness, abnormal
tunes down T cell responses to antigen in vivo in the gait; 3, complete hind limb paralysis; 4, complete hind limb paralysis
absence of traditional anergy in vitro. and forelimb weakness or paralysis
That T cells might be able to tune signaling thresholds
in the periphery was suggested to account for loss of Production of Hybrid Antibodies
reactivity upon exposure to some forms of persistent DNA coding for MOG peptide with spacing residues on both sides
was cloned into the C terminus of the heavy chains of a hybrid anti-self-antigens (Grossman and Paul, 1992, 2001; Pape et
DEC-205 and III/10, an isotype control (previously named GLII7),al., 1998; Singh and Schwartz, 2003). One example of
(Hawiger et al., 2001) using synthetic oligonucleotides:this type of adaptation is induced by CTLA-4 ligation,
5CTAGCGACATGGCCAAGAAGGAGACAGTCTGGAGGCTCGA
which produces T cells that are anergic by virtue of GGAGTTCGGTAGGTTCAGGATTAGCCCCGGTAAGAACGCCACA
being unresponsive to TCR crosslinking (Gross et al., 5GGTATGGAGGTCGGTTGGTATAGGAGCCCCTTCAGCAGGG
1990; Krummel and Allison, 1995; Latchman et al., 2001; TCGTCCACCTCTATAGGAACGGTAAGGACCAGGACGCCTGA
TAGGCPerez et al., 1997; Tivol et al., 1995; Walunas et al., 1994).
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5GGCCGCCTATCAGGCGTCCTGGTCCTTACCGTTCCTATAG References
AGGTGGACGACCCTGCTGAAGGGGCTCCTATACCAACCGACCTC
5CATACCTGTGGCGTTCTTACCGGGGCTAATCCTGAACCTAC Adler, A.J., Marsh, D.W., Yochum, G.S., Guzzo, J.L., Nigam, A.,
CGAACTCCTCGAGCCTCCAGACTGTCTCCTTCTTGGCCATGTCG Nelson, W.G., and Pardoll, D.M. (1998). CD4 T cell tolerance to
Hybrid antibodies were expressed in 293 cells by transient trans- parenchymal self-antigens requires presentation by bone marrow-
fection using calcium/phosphate. Cells were grown in serum free derived antigen-presenting cells. J. Exp. Med. 187, 1555–1564.
DMEM supplemented with Nutridoma SP (Roche). Antibodies were Anderson, M.S., Venanzi, E.S., Klein, L., Chen, Z., Berzins, S.P.,
purified on Protein G columns (Pharmacia). The concentrations of Turley, S.J., von Boehmer, H., Bronson, R., Dierich, A., Benoist, C.,
antibodies were determined by ELISA using goat anti-mouse IgG1 and Mathis, D. (2002). Projection of an immunological self shadow
and mouse IgG1 antibodies as a standard (Jackson Immunotech). within the thymus by the aire protein. Science 298, 1395–1401.
Apostolou, I., Sarukhan, A., Klein, L., and von Boehmer, H. (2002).
Antibodies for Flow Cytometry and In Vitro Origin of regulatory T cells with known specificity for antigen. Nat.
Tissue Culture Experiments Immunol. 3, 756–763.
anti-CD5- (53-7.3), CD4- (L3T4), CD11c- (HL3), B220- (RA3-6B2),
Asano, M., Toda, M., Sakaguchi, N., and Sakaguchi, S. (1996). Auto-CD3- (145-2C11), CD80(B7-1)-(16-10A1), CD86(B7-2)- (GL1),
immune disease as a consequence of developmental abnormalityCD45.1- (A20), CD45.2- (104), CD44- (IM7), CD28- (37.51), CD25-
of a T cell subpopulation. J. Exp. Med. 184, 387–396.(7D4), CD62L- (10E9.6), CD69- (H1.2F3), CTLA-4- (UC10-4F10-11),
Azzam, H.S., Grinberg, A., Lui, K., Shen, H., Shores, E.W., and Love,I-Ab (AF6-120.1), ICOS (7E.17G9), control (R35-95) antibodies,
P.E. (1998). CD5 expression is developmentally regulated by T cellAnnexin V-PE and 7-amino-actinomycin (7-AAD) were from Phar-
receptor (TCR) signals and TCR avidity. J. Exp. Med. 188, 2301–2311.Mingen.
Anti-rat and hamster goat polyclonal antibodies used in in vitro Azzam, H.S., DeJarnette, J.B., Huang, K., Emmons, R., Park, C.S.,
tissue culture experiments were from Jackson Laboratories. Sommers, C.L., El-Khoury, D., Shores, E.W., and Love, P.E. (2001).
Flow cytometric assay for caspase activation was performed with Fine tuning of TCR signaling by CD5. J. Immunol. 166, 5464–5472.
CaspaTag caspase inhibitors conjugated with FITC (Intragen) ac- Barthlott, T., Kassiotis, G., and Stockinger, B. (2003). T cell regulation
cording to the manufacturers’ protocol. as a side effect of homeostasis and competition. J. Exp. Med.
197, 451–460.
Cell Culture and Proliferation Assays
Belz, G.T., Behrens, G.M., Smith, C.M., Miller, J.F., Jones, C., Lejon,Pooled auxiliary, brachial, inguinal, and popliteal lymph nodes were
K., Fathman, C.G., Mueller, S.N., Shortman, K., Carbone, F.R., anddissociated in 5% FCS RPMI and incubated in presence of collagen-
Heath, W.R. (2002). The CD8alpha() dendritic cell is responsiblease (Roche) and EDTA as described (Inaba et al., 1997). For antigen
for inducing peripheral self-tolerance to tissue-associated antigens.presentation CD11c and CD19 cells were purified using mi-
J. Exp. Med. 196, 1099–1104.crobeads coupled to anti-mouse CD11c or CD19 IgG (Miltenyi) and
Bettelli, E., Pagany, M., Weiner, H.L., Linington, C., Sobel, R.A., andirradiated with 1500 R. CD4 T cells were purified by depletion using
Kuchroo, V.K. (2003). Myelin oligodendrocyte glycoprotein-specificmicrobeads coupled with anti-CD8, CD19, or CD11c from Miltenyi.
T cell receptor transgenic mice develop spontaneous autoimmuneIn antigen loading experiments the isolated antigen-presenting cells
optic neuritis. J. Exp. Med. 197, 1073–1081.from each experimental group were cultured in 96-well plates with
2  105 purified anti-MOG CD4 T cells. Cultures were maintained Bhandoola, A., Bosselut, R., Yu, Q., Cowan, M.L., Feigenbaum, L.,
for 60 hr with 3H-thymidine (1 Ci) added for the last 8 hr. Love, P.E., and Singer, A. (2002). CD5-mediated inhibition of TCR
For T cell proliferation assays in adoptive transfer recipients, 9  signaling during intrathymic selection and development does not
104 irradiated CD11c cells isolated from spleens of C57Bl/6 mice require the CD5 extracellular domain. Eur. J. Immunol. 32, 1811–
were cultured in 96-well plates with 3 105 T cells from each experi- 1817.
mental group. Synthetic MOG peptide, at final concentration of 100 Bonifaz, L., Bonnyay, D., Mahnke, K., Rivera, M., Nussenzweig, M.C.,
g/ml, was added to half of the cultures. Cultures were maintained and Steinman, R.M. (2002). Efficient targeting of protein antigen to
for 48 hr with 3H-thymidine (1 Ci/ml) added for the last 8 hr. Syn- the dendritic cell receptor DEC-205 in the steady state leads to
thetic MOG 35-55 peptide was provided by the HHMI Keck Biotech- antigen presentation on major histocompatibility complex class I
nology Resource Center. products and peripheral CD8() T cell tolerance. J. Exp. Med.
For experiments with cross-linking of CD3, CD28, and CD5; 105 196, 1627–1638.
of CD4 T cells were cultured in 96-well plates in presence of 10
Brossard, C., Semichon, M., Trautmann, A., and Bismuth, G. (2003).
g/ml of purified antibodies (BD Pharmingen). Polyclonal goat anti-
CD5 inhibits signaling at the immunological synapse without im-rat and anti-hamster antibodies (Jackson) were used (15 g/ml) as
pairing its formation. J. Immunol. 170, 4623–4629.secondary cross-linking reagents.
Caux, C., Massacrier, C., Vanbervliet, B., Dubois, B., Van Kooten,
C., Durand, I., and Banchereau, J. (1994). Activation of human den-Adoptive Transfer
dritic cells through CD40 cross-linking. J. Exp. Med. 180, 1263–1272.CD4 cells from anti-MOG TCR transgenic mice were isolated by
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Raine, C.S., Goverman, J., and Lenardo, M.J. (1994). T cell deletioncells injected intravenously per mouse. Alternatively, before deple-
in high antigen dose therapy of autoimmune encephalomyelitis. Sci-tion total cells were labeled with 3 M CFSE (Molecular Probes) in
ence 263, 1139–1143.5% FCS RPMI at 37 C for 25 min and washed 3.
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